Maravai LifeSciences (NASDAQ:MRVI) Reaches New 12-Month High – Should You Buy?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $5.32 and last traded at $5.2550, with a volume of 533257 shares changing hands. The stock had previously closed at $5.01.

Wall Street Analyst Weigh In

MRVI has been the topic of a number of recent research reports. UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Wells Fargo & Company lifted their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.50.

Maravai LifeSciences Price Performance

The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The firm has a market cap of $1.34 billion, a P/E ratio of -7.30 and a beta of 0.72. The business has a fifty day moving average of $4.14 and a 200 day moving average of $3.66.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The business had revenue of $65.84 million during the quarter, compared to analysts’ expectations of $53.00 million. On average, sell-side analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current year.

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the sale, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. The trade was a 6.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its holdings in shares of Maravai LifeSciences by 49.0% during the first quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Maravai LifeSciences by 0.9% during the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock worth $12,069,000 after acquiring an additional 39,600 shares during the period. Public Employees Retirement System of Ohio bought a new stake in shares of Maravai LifeSciences during the first quarter worth approximately $238,000. Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences by 64.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock worth $4,015,000 after acquiring an additional 558,050 shares during the period. Finally, Brummer Multi Strategy AB boosted its holdings in shares of Maravai LifeSciences by 66.0% during the first quarter. Brummer Multi Strategy AB now owns 759,743 shares of the company’s stock worth $2,150,000 after acquiring an additional 302,036 shares during the period. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.